Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation

Bone Marrow Transplantation

Volumn 20, Issue 3, 1997, Pages 257-260

  Trede, N S ^a,e   Warwick, A B ^b   Rosoff, P M ^c   Rohrer, R ^d   Bierer, B E ^a   Guinan, E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Midwest children'S' Cancer Center   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bone marrow transplantation; FK506; Liver transplantation; Severe aplastic anemia

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CASE REPORT; CONDITIONING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS HEPATITIS;

EID: 0030743324     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700872     Document Type: Article

References (22)

1. Tzakis AG, Arditi M, Whitington PF et al. Aplastic anemia complicating orthotopic liver transplantation for non-A, non-B hepatitis. New Engl J Med 1988; 319: 393-396.
2. Cattral MS, Langnas AN, Markin RS et al. Aplastic anemia after liver transplantation for fulminant liver failure. Hepatology 1994; 20: 813-818.
3. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood 1995; 12: 3367-3377.
4. Dugan MJ, Rouch DA, Akard LP et al. Successful allogeneic bone marrow transplantation in an adult with aplastic anemia following orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Bone Marrow Transplant 1993; 12: 417-419.
5. Kawahara K, Storb R, Sanders J, Petersen FB. Successful allogeneic bone marrow transplantation in a 6.5-year-old male for severe aplastic anemia complicating orthotopic liver transplantation for fulminant non-A-non-B hepatitis. Blood 1991; 78: 1140-1143.
6. Kino T, Hatanaka H, Hashimoto M et al. FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biologic characteristics. J Antibiot 1987; 40: 1256-1265.
7. Kino T, Inamura T, Sakai F et al. Effect of FK506 on human mixed lymphocyte reaction in vitro. Transplant Proc 1987; 19 (Suppl. 6): 36-39.
8. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. New Engl J Med 1994; 331: 1110-1115.
9. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-428.
10. Storb R, Raff RF, Appelbaum FR et al. FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation 1993; 56: 800-807.
11. Markus PM, Cai MX, Ming W et al. Prevention of graft-ver-sus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 1991; 52: 590-594.
12. Blazar BR, Taylor PA, Fitzsimmons WE, Vallera DA. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts interfering with mature peripheral T cell expansion post-transplantation. J Immunol 1994; 153: 1836-1846.
13. Masaoka T, Shibata H, Kakishita E et al. Phase II study of FK506 for allogeneic bone marrow transplantation. Transplant Proc 1991; 22: 3228-3231.
14. Tzakis AG, Abu-Elmagd K, Fung JJ et al. FK506 rescue in chronic graft-versus-host disease after bone marrow transplantation. Transplant Proc 1991; 23: 3225-3227.
15. Fay JW, Wingard JR, Antin JH et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996; 87: 3514-3519.
16. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and mini-dose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-4389.
17. Kanamura A, Takemoto Y, Kakishita E et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Bone Marrow Transplant 1995; 15: 885-889.
18. Koehler MT, Howrie D, Mirro J et al. FK506 (tacrolimus) in the treatment of steroid-resistance acute graft-versus-host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 1995; 15: 895-899.
19. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-142.
20. Storb R, Deeg HJ, Farewell V et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination to methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119-125.
21. Cooper MH, Patrene KD, Vecchini F et al. Short-term reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD. Bone Marrow Transplant 1994; 14: 355-362.
22. Cox KL, Lawrence LS, Garcia-Kennedy R et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524-529.